key: cord-1016455-z5hzqzn3
authors: Leclère, Jean-Baptiste; Fournel, Ludovic; Etienne, Harry; Al Zreibi, Charbel; Onorati, Ilaria; Roussel, Arnaud; Castier, Yves; Martinod, Emmanuel; Le Pimpec-Barthes, Françoise; Alifano, Marco; Assouad, Jalal; Mordant, Pierre
title: Maintaining surgical treatment of non-small cell lung cancer during the COVID-19 pandemic in Paris
date: 2020-10-08
journal: Ann Thorac Surg
DOI: 10.1016/j.athoracsur.2020.08.007
sha: f66629258d9f2cde23bb25702672ff2b0a8855a5
doc_id: 1016455
cord_uid: z5hzqzn3

Background Coronavirus Disease 2019 (COVID-19) outbreak was officially declared in France on March 14th 2020. The objective of this study is to report the incidence and outcome of COVID-19 following surgical resection of non-small cell lung cancer (NSCLC) in Paris Public Hospitals during the pandemic. Methods We retrospective analyzed a prospective database including all patients who underwent NSCLC resection between March 14th 2020 and May 11th 2020 in the 5 thoracic surgery units of Paris Public Hospitals. The primary endpoint was the occurrence of SARS-CoV-2 infection during the first 30 days following surgery. Results Study group included 115 patients (male 57%, age 64.6±10.7, adenocarcinoma 66%, cT1 62%, cN0 82%). During the first month after surgery, 6 patients (5%) were diagnosed with COVID-19. As compared to COVID negative patients, COVID positive patients were more likely to be operated on during the first month of the pandemic (100% vs. 54%, p=0.03) and to be on corticosteroids preoperatively (33% vs. 4%, p=0.03). Postoperative COVID-19 was associated with an increased rate of readmission (50% vs. 5%, p=0.004), but no difference in 30-day morbidity (for the study group: grade 2, 24%; grade 3, 7%; grade 4, 1%) or mortality (n=1 COVID negative patient, 0.9%). Immediate oncological outcomes did not differ significantly between groups (R0 resection 99%, nodal upstaging 14%, adjuvant treatment 29%). Conclusions During the COVID-19 pandemic, surgical treatment of NSCLC was associated with a rate of postoperative COVID-19 of 5% with a significant impact on readmissions but not on other outcomes studied.

After an early phase of slow virus spread, the Coronavirus Disease 2019 (COVID-19) outbreak was officially declared in France on March 14 th 2020, and a national lockdown was established on March 16 th 2020. By the end of March, there were 52 128 confirmed COVID-19 cases in France, including 22 757 patients requiring hospitalization, 5 565 requiring intensive care, and a death toll of 3 523 people (1) . After the eastern region, Paris and its vicinities quickly appeared to be the second epicenter of the disease in France, stretching the health care system with a huge number of patients, forcing Paris hospitals to double their intensive care unit (ICU) capacity, to transfer ICU patients to distant regional hospitals, and to postpone non-urgent surgical procedures (1) .

Whether surgical resection of cancer can be considered an urgent or semi-urgent procedure is questionable. Specifically, there is no consensus on the impact of delay in the surgical management of non-small cell lung cancer (NSCLC). Yang et al. analyzed the United States National Cancer Database and found that an interval longer than 6 to 12 weeks between diagnosis of early-stage NSCLC and surgery was associated with worse survival (2) . General guidelines from the National Comprehensive Cancer Network state that treatment delays should be avoided (3) while those from the European Society for Medical Oncology (4) and the American College of Chest Physicians (5) do not mention any time limit to initiate surgical intervention. Conversely, European Nordic countries have organized integrated cancer pathways to assure a rapid and well-coordinated course of treatment, and low-risk patients with early stages NSCLC are required to receive surgery within 14 calendar days following completion of diagnostic work-up (6).

At the beginning of the pandemic, there was no specific guideline to address the surgical management of NSCLC in this particular period. The ethical guidelines driving the care of COVID-19 patients were already widely discussed, and included maximizing benefits, treating equally, promoting and rewarding instrumental value, and giving priority to the worst off (7). Even if the management of non-COVID-19 patients was not discussed by then, we considered that the value of maximizing benefits during a pandemic should be applied equally to all patients whatever their underlying disease. Accordingly, the French High Counsel of Public Health (Haut Conseil de Santé Publique) published guidelines on the care of cancer patients during a pandemic, and advised to prioritize cancer care to patients with a high likelihood of cure (8). In this context, we organized a specific COVID-free surgical path to preserve the surgical resections of NSCLC planned with curative intend in low risk patients and patients whose tumor was to be operated rapidly. The objective of J o u r n a l P r e -p r o o f this study is to report the incidence and outcome of COVID-19 following surgical resection of NSCLC in Paris Public Hospital during the SARS-CoV-2 pandemic.

Study design. We set a retrospective study of a prospectively maintained multicentric administrative database, including all patients who underwent surgical treatment of NSCLC in Paris, France, from the official announcement of the COVID-19 outbreak until the end of the national lockdown.

Inclusion criteria were patients with NSCLC undergoing surgery with curative intend from March 14 th 2020 to May 11 th 2020 in the thoracic surgery departments of Avicenne Hospital, Bichat Hospital, Cochin Hospital, Georges-Pompidou European Hospital, and Tenon Hospital, all part of Assistance Publique -Hôpitaux de Paris (AP-HP), a network of 39 public hospitals totalizing 20.000 beds in Paris and its vicinities. We reviewed patients' characteristics, surgical procedures, short term outcomes, pathology results, and occurrence of a postoperative COVID-19. The study was split in two timeperiods. The early time-period was set from March 14th to April 14th, and corresponded to an increase in the number of hospitalized COVID-19 cases in our institution followed by a plateau around 4500 patients or 22% of AP-HP capacities. The late time-period was set from April 15th to May 11th, and corresponded to a progressive decline in the number of hospitalized COVID-19 patients.

Endpoints. The primary endpoint was the incidence and prognosis of PCR-proven postoperative COVID-19 during the first 30 days following surgery (30-day COVID-19). Secondary endpoints included the occurrence of any complication according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0) during the first 30 days following surgery (30-day morbidity), the occurrence of death of any cause during the first 30 days following surgery (30-day mortality), the proportion of patients with complete resection on the surgical specimen (R0 resection), and the proportion of patients with suspected COVID-19 on the pathologic examination of the surgical specimen (day 0 COVID-19).

Ethical aspects. All patients signed an informed consent to authorize prospective data collection and retrospective data analysis. The database was declared to the National Board for Informatics and J o u r n a l P r e -p r o o f Preoperative management. All cases were discussed pre and postoperatively during a multidisciplinary meeting (MDM) including a pulmonologist, an oncologist, a thoracic surgeon, a radiation therapist, a radiologist, and a pathologist to confirm the surgical management of NSCLC and its timing in case of multimodal strategy. The risk of postoperative mortality was estimated using the Thoracoscore (9). Thoracic surgery units were organized as COVID-free units where every suspected COVID-19 case was immediately transferred to a medical unit dedicated to COVID-19 patients. For surgical candidates, screening of COVID-19 was performed the day before surgery. In the early time- Surgery. When the surgery was confirmed, patients were equipped with a surgical mask and transferred to the operating room. The anesthesiology team wore FFP2 masks during intubation, bronchoscopy, and endotracheal tube manipulation to ensure selective ventilation. The surgical team wore surgical masks during the procedure. The surgical procedure was performed according to MDM decision and surgeon's preference, with a closure of the bronchial stump using double side endostappler to avoid bronchial opening whenever feasible. Patients wore a surgical mask during their transfer to the recovery room, in the recovery room, and during their transfer back to their room in the thoracic surgery unit. Postoperative Chest-CT and SARS-CoV-2 PCR were performed only if a postoperative COVID-19 infection was suspected, during initial hospitalization, after discharge, or upon readmission. In case of postoperative COVID-19, the severity of lung involvement was estimated on chest CT (10).

with Chi-squared or Fisher's exact test when appropriate. Continuous variables with normal distribution were reported as mean ± standard deviation and compared using the Student's t-test or Welch Two Sample t-test when appropriate. Continuous variables with non-normal distribution were reported as median [interquartile range] and compared using the Mann-Whitney test. The 30-day follow-up was complete for all patients. All data analyses were conducted with two-sided tests, without adjustment for multiple comparisons. A p-value less than 0.05 was considered significant. Table 1 .

Preoperative work-up. Preoperative tumor assessment is presented in Table 2 . Average tumor size was 28.4±15.7mm (range 5-90). Eight patients (7%) underwent induction chemotherapy. In one patient, a recent CT scan retrospectively showed additional alveolar opacities around a 4-cm tumor.

Surgical Treatment. Details of surgical management are developed in Table 3 . One patient was operated in emergency conditions. Three patients (3%) underwent delayed surgery because of the pandemic context. One patient died six days after a right pneumonectomy due to bacterial pneumonia and pulmonary embolism with a negative COVID-19 testing.

Oncological outcome. Immediate oncological outcomes are presented in Table 4 . One patient (1%) had R1 resection. Postoperative MDM decision was available in 77 patients, among which adjuvant chemotherapy was decided in 29 (29%), chemoradiotherapy in 4 (5%), and targeted therapy in 1 (1%). 

COVID-19 Dashboard

Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma

Non-Small Cell Lung Cancer, Version 6

Adk: adenocarcinoma; CT: chemotherapy; IHD: ischemic heart disease; ACE: angiotensin converting enzyme inhibitor; IS: immunosuppression; SCC: Squamous cell carcinoma; SVC: superior vena cava

COPD: chronic obstructive pulmonary disease